Mallinckrodt tamper-resistant drug performs well for bunion patients

Mallinckrodt ($MNK) has released good-news data from a Phase III study of an experimental pain drug for use by patients after bunion surgery. In June, the Dublin, Ireland-based drugmaker submitted a new drug application for priority review for the therapy, an oral extended-release combination of oxycodone and acetaminophen. Mallinckrodt's treatment will offer a level of resistance to tampering with the highly addictive product, a quality that could set it apart in the competitive pain drug arena; BMO Capital Markets analyst David Maris told Reuters sales of the therapy could peak at $200 million by 2017. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.